Health Economics›Esophageal cancer›Consolidation after definitive therapy

Consolidation after definitive therapy

Esophageal cancer · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
FOLFOX4 Variant #01	—	R 2 064	14d	~8.0 mo	~12.9 mo	~18	~R 37 145 PFS proxy · indirect	14
Cisplatin and Fluorouracil (CF) Variant #29	—	R 1 900	21d	—	~9.8 mo	—	—	4

2 of 2 regimens shown